Pluristem (PSTI) - Total Liabilities

Latest as of March 2022: ILA38.98 Million ILA ≈ $104.51K USD

Based on the latest financial reports, Pluristem (PSTI) has total liabilities worth ILA38.98 Million ILA (≈ $104.51K USD) as of March 2022. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Pluristem (PSTI) cash flow conversion to assess how effectively this company generates cash.

Pluristem - Total Liabilities Trend (2014–2021)

This chart illustrates how Pluristem's total liabilities have evolved over time, based on quarterly financial data. Check Pluristem asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Pluristem Competitors by Total Liabilities

The table below lists competitors of Pluristem ranked by their total liabilities.

Company Country Total Liabilities
Salcon Engineering Berhad
KLSE:8567
Malaysia RM212.73 Million
Hunya Foods Co Ltd
TW:1236
Taiwan NT$1.26 Billion
Al-Salam Real Estate Investment Trust
KLSE:5269
Malaysia RM662.78 Million
Taiwan Alpha Electronic Co Ltd
TWO:6204
Taiwan NT$157.31 Million
Thitikorn Public Company Limited
BK:TK
Thailand ฿297.83 Million
Fine Blanking & Tool Co Ltd
TWO:4535
Taiwan NT$326.44 Million
Dawonsys Co.Ltd
KQ:068240
Korea ₩1.13 Trillion
Song Shang Electronics Co Ltd
TWO:6156
Taiwan NT$3.74 Billion

Liability Composition Analysis (2014–2021)

This chart breaks down Pluristem's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pluristem stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 8.22 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.02 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.49 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pluristem's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pluristem (2014–2021)

The table below shows the annual total liabilities of Pluristem from 2014 to 2021.

Year Total Liabilities Change
2021-06-30 ILA36.39 Million
≈ $97.55K
+285.82%
2020-06-30 ILA9.43 Million
≈ $25.28K
-0.61%
2019-06-30 ILA9.49 Million
≈ $25.44K
-9.22%
2018-06-30 ILA10.45 Million
≈ $28.02K
+43.53%
2017-06-30 ILA7.28 Million
≈ $19.53K
-6.45%
2016-06-30 ILA7.79 Million
≈ $20.87K
-22.24%
2015-06-30 ILA10.01 Million
≈ $26.84K
-15.87%
2014-06-30 ILA11.90 Million
≈ $31.90K
--

About Pluristem

TA:PSTI Israel Biotechnology & Medical Research
Market Cap
$65.47 Million
ILA24.42 Billion ILA
Market Cap Rank
#20955 Global
#284 in Israel
Share Price
ILA754.90
Change (1 day)
-4.71%
52-Week Range
ILA754.90 - ILA1900.00
All Time High
ILA72010.00
About

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase I… Read more